The global market is expected to enjoy a valuation of USD 4.4 Billion by the end of the year 2023, and further expand at a CAGR of 2.72% to reach a valuation of USD 5.8 Billion by the year 2033. According to the recent study by Future Market Insights, anti- psychotic drugs are leading the market with an expected share of about 40.2% in the year 2023, within the global market.
Market Outlook
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 4.3 Billion |
| Market Value 2023 | USD 4.4 Billion |
| Market Value 2033 | USD 5.8 Billion |
| CAGR 2023 to 2033 | 2.72% |
| Market Share of Top 5 Countries | 73.6% |
| Key Market Players | AbbVie Inc.; Glaxo SmithKline (GSK); ELI Lilly and Company; Janssen Pharmaceuticals; Astellas Pharma Inc.; Bristol Myers Squibb; Gedeon Richter Plc.; H. Lundbeck A/S; Pfizer Inc.; Novartis AG; Otsuka Holdings Co. Ltd; Validus Pharmaceuticals LLC |
Changing perspective about the importance of mental health treatments is anticipated to raise the sale of over the counter meds for bipolar disorder. According to the Global Burden of Disease report 2017, the prevalence of bipolar disorder ranges from 0.3% to 1.2% among different regions. In recent years, there has been growing awareness about the disorder, shifting the perspective for it as a mental ailment creating a surge in the sale of natural bipolar medication.
With the changing perspective about mental health, the demand for natural bipolar meds or drugs is anticipated to grow by the patients suffering from such disease. A similar category of drugs, commonly known as bipolar depression treatment medication, is increasingly available in all parts of the world.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for bipolar disorder drugs and treatment was approximately 20.3% of the overall USD 21.2 Billion of the global psychotropic drugs market in 2022.
The sale of bipolar disorder drugs and treatment expanded at a CAGR of 2.10% from 2017 to 2022.
The market for bipolar disorder drugs and treatment was mildly hit by the COVID-19 pandemic restrictions. As there were widespread positive cases of patients infected by the novel coronavirus, most of the resources and professionals of the healthcare sector were diverted towards the management of the COVID-19 menace.
Particularly the demand for medication for bipolar from the hospital and healthcare institutions dropped significantly. Surprisingly enough, the number of patients diagnosed with bipolar disorders increased significantly during the worldwide shutdown. This fact is hypothesized from the information of the increase in the volume of over the counter medicine for bipolar available during the pandemic times. However, the market growth for prescribed drugs continued through the increase in online availability of bipolar meds on e-commerce sites.
As the healthcare sector was kept as the most prioritized business sector, the drugs market recovered from the jolt of the pandemic within a few days. There were also some remarkable developments in the field of herbal medicine for bipolar disorder that has emerged as a successful niche for the bipolar disorder drugs and treatment market.
Thus, owing to the aforementioned factors, the global bipolar disorder drugs and treatment market is expected to grow at a CAGR of 2.72% during the forecast period from 2023 to 2033.
| Market Statistics | Details |
|---|---|
| Jan to Jun (H1), 2021 (A) | 1.91% |
| Jul to Dec (H2), 2021 (A) | 2.43% |
| Jan to Jun (H1),2022 Projected (P) | 1.73% |
| Jan to Jun (H1),2022 Outlook (O) | 1.86% |
| Jul to Dec (H2), 2022 Outlook (O) | 2.68% |
| Jul to Dec (H2), 2022 Projected (P) | 2.43% |
| Jan to Jun (H1), 2023 Projected (P) | 2.12% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 12↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | (-) 6↓ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 25↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 25↑ |
Principal Consultant
Bipolar disorders have been recognized as the 6th largest contributor in the total disabled person in the world, by World Health Organizations or WHO. To mitigate the serious consequences, modern medical science has developed therapeutic drugs for its treatment that is available as over the counter meds in the drug stores.
Previously the consciousness and awareness about the remedial measures for any type of mental disorder were below the level, resulting in less demand for good medicine for bipolar disorder produced by the pharmaceutical companies. However, in recent days with the growth in digital media, the acceptance of methods for treatment of bipolar is reflected in the huge growth in sales of over the counter meds for bipolar cases.
There is also some old age natural medication for bipolar disorder that is being actively researched and developed by pharmaceutical companies to augment their customer base. Many market players have succeeded in creating brand values by supplying mood stabilizers online to customers.
The lithium (Li) element used in the production of anti-mania drugs can cause anorexia if taken by an overdose. Also, the prolonged use of lithium can damage the effects of vasopressin hormone that can result in diabetes insipid, as cited by many reports. This tact can hinder the wider adaptability of bipolar over the counter meds for disorder treatment as well.
As the typical age group for the emergence of any symptom of bipolar disorder is around 20 to 25 years, so it often gets neglected by the parents. This delays the tremendous procedure for bipolar disorders and reduces the effectiveness of natural bipolar meds, and hampers the value of the drug in the market. Over the years, a lot of generic medicines have been coming into the market competing with the well-established market chains of OTC mood stabilizer medications.
Addiction of the body to such types of drugs is another major concern for the use of bipolar treatment drugs by the patients. There is also very less number of anticonvulsant drugs approved for use as bipolar disorder medication over the counter that can hamper the rapid growth of the global market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | USA |
|---|---|
| 2023 | 52.90% |
| 2033 | 54.20% |
| BPS | 129 |
| Country | Germany |
|---|---|
| 2023 | 6.90% |
| 2033 | 6.90% |
| BPS | (-) 2 |
| Country | United kingdom |
|---|---|
| 2023 | 5.30% |
| 2033 | 5.40% |
| BPS | 9 |
| Country | Brazil |
|---|---|
| 2023 | 4.40% |
| 2033 | 4.40% |
| BPS | 7 |
| Country | France |
|---|---|
| 2023 | 4.10% |
| 2033 | 4.10% |
| BPS | 5 |
The USA is set to obtain a share of around 52.90% in the global market, in 2023.
National Institute of Mental Health (NIMH) provides data for the number of people in USA developing bipolar disorder symptoms at approximately 10 million. By the support of government initiatives and dissemination of knowledge about the mental condition of such patients, there has been an encouraging environment for their treatment through proper medication for bipolar disorder.
The increase in disruption of daily lifestyle like insufficient sleep, wrong food habits or substance abuse and higher stress level in the youngster is the reason for the increasing sale of mood stabilizer medications over the counter, particularly in the USA.
Germany is set to hold a market share of nearly 6.90% in the global bipolar disorder drugs and treatment market in 2023.
Strong policies to regulate the sale of over the counter medication for bipolar disorder is expected to enhance the growth of bipolar disorder drugs and the treatment market in this region.
China is set to expand at a CAGR of 2.50% in the global market, over the forecast period.
A rising frequency of mental diseases, greater awareness of bipolar disorders, and higher investments by major firms are all contributing to China's expected position as the market with the highest growth. A high patient population and rising public awareness of mental health issues have driven the market in the nation.
Anti-psychotic drugs segment leads the market and is expected to hold a share of around 40.23% globally, in 2023.
Since they were first introduced into psychiatric therapy, antipsychotic drugs have been used to treat acute episodes of bipolar disease and prevent relapses. With the release of second-generation antipsychotic drugs, there has been a resurgence in interest in the ability of this class of drugs to treat manic-depression, which has increased the market share.
Bipolar I disorder segment is set to hold a global market share of around 38.46% in 2023.
Manic episodes that continue at least seven days or manic symptoms severe enough to require emergency hospitalization are signs of bipolar I disorder. According to estimates from the National Institute of Mental Health (2020), 4.4% of American adults may experience bipolar illness at some point in their lifetime, which has sparked interest in the market segment globally.
Hospital pharmacies is set to hold nearly half of the global a market share in 2023.
Growing rates of hospitalization as well as rising awareness on mental health globally has propelled the growth of this segment. Institutionalized patients have access to prescription drugs required for alleviation of disease symptoms, as well as for therapeutic purposes. Moreover, with access to adequate distribution networks, the segment is expected to gain traction over the forecast period, owed to greater accessibility of medications.
The main strategies adopted by the market players include the development of new drugs for bipolar disorder over the counter medication by investing in research and development (R&D) activities. Acquiring approvals for such over the counter medications is the most important step in gaining recognition for the newly developed medicines.
Expanding business activities by acquisition and merger of the locally established manufacturers supplying mood stabilizer medications over the counter in any area.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the bipolar disorder drugs and treatment space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Drug Class, Bipolar Disorder, Distribution Channel, and Region |
| Key Companies Profiled | AbbVie Inc.; Glaxo SmithKline (GSK); ELI Lilly and Company; Janssen Pharmaceuticals; Astellas Pharma Inc.; Bristol Myers Squibb; Gedeon Richter Plc.; H. Lundbeck A/S; Pfizer Inc.; Novartis AG; Otsuka Holdings Co. Ltd; Validus Pharmaceuticals LLC |
| Pricing | Available upon Request |
In 2023, the market is expected to attain USD 4.4 billion.
The sales are to spur to USD 5.8 billion in 2033.
Through 2033, the market is set to evolve at a CAGR of 2.72%.
From 2018 to 2022, the global market advanced at a CAGR of 2.1%.
In 2023, the United States is expected to possess a global market share of 52.90%.
In 2023, Germany is anticipated to have a 6.90% market share globally.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Market Background 6. COVID-19 Crisis Analysis 7. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class 8.1. Mood Stabilizer 8.2. Anticonvulsants 8.3. Anti-Psychotic Drugs 8.4. Anti-Depressant Drugs 8.5. Anti-Anxiety Drugs 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Bipolar Disorder 9.1. Bipolar I Disorder 9.2. Bipolar II Disorder 9.3. Cyclothymic Disorder 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Hospital Pharmacies 10.2. Retail Pharmacies 10.3. Online Pharmacies 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 11.1. North America 11.2. Latin America 11.3. Europe 11.4. East Asia 11.5. South Asia 11.6. Oceania 11.7. Middle East and Africa (MEA) 12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. Oceania Market 2017-2022 and Forecast 2023-2033 18. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Market Structure Analysis 20. Competition Analysis 20.1. AbbVie Inc. 20.2. Glaxo SmithKline (GSK) 20.3. ELI Lilly and Company 20.4. Janssen Pharmaceuticals 20.5. Astellas Pharma Inc. 20.6. Bristol Myers Squibb 20.7. Gedeon Richter Plc. 20.8. H. Lundbeck A/S 20.9. Pfizer Inc. 20.10. Novartis AG 20.11. Otsuka Holdings Co. Ltd 20.12. Validus Pharmaceuticals LLC 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Bipolar Disorder Drugs and Treatment Market
